Philip Frick, APRN
Psychiatric/Mental Health · Manchester, CTNPI 1689627044
Payments from drug & device makers
Across 1,165 payments — averaging $26.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$13K
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Lundbeck LLC$2K
- Sunovion Pharmaceuticals Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- plus $8K from 21 others
What the payments were for
- Speaking & faculty fees$10,76735%
- Food & beverage$20,19065%
- Education$2221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 114 | $12,949 |
| AbbVie | 157 | $2,721 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 142 | $2,605 |
| Lundbeck LLC | 140 | $2,306 |
| Sunovion Pharmaceuticals Inc. | 94 | $1,694 |
| Neurocrine Biosciences, Inc. | 75 | $1,402 |
| Johnson & Johnson | 75 | $1,243 |
| Alkermes, Inc. | 90 | $1,183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $1,016 |
| Vanda Pharmaceuticals Inc. | 39 | $787 |
| Axsome Therapeutics, Inc. | 29 | $592 |
| Bausch Health US, LLC | 34 | $570 |
| Teva Pharmaceuticals USA, Inc. | 28 | $461 |
| Avanir Pharmaceuticals, Inc. | 15 | $332 |
| Corium, LLC | 18 | $285 |
| Idorsia Pharmaceuticals US Inc | 17 | $243 |
| E.r. Squibb & Sons, L.L.C. | 13 | $206 |
| Merck | 9 | $168 |
| Eisai Inc. | 6 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $61 |
| Luye Pharma (USA) Ltd. | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Indivior Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| TMS Neurohealth Centers Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$9,933
- ABILIFY MAINTENA$885
How this compares
$31,178 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $186,649 |
| SpravatoEsketamine Hcl | 36 | $42,175 |
| RexultiBrexpiprazole | 23 | $38,390 |
| CaplytaLumateperone Tosylate | 21 | $34,637 |
| VraylarCariprazine Hcl | 17 | $29,359 |
| TrintellixVortioxetine Hydrobromide | 18 | $12,597 |
| QuviviqDaridorexant Hcl | 11 | $5,377 |
| Asenapine Maleate | 16 | $4,712 |
| Bupropion XlBupropion Hcl | 108 | $2,120 |
| Lurasidone Hcl | 25 | $1,539 |
| Duloxetine Hcl | 47 | $1,297 |
| Risperidone | 39 | $1,176 |
| Gabapentin | 64 | $1,118 |
| Quetiapine Fumarate | 41 | $957 |
| Trazodone Hcl | 64 | $923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,402 | $186,64924 claims |
| Johnson & JohnsonSpravato | $1,243 | $42,17536 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $12,949 | $38,39023 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,605 | $34,63721 claims |
| AbbVieVraylar | $2,721 | $29,35917 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,016 | $12,59718 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $243 | $5,37711 claims |
| Almatica Pharma LLCSertraline Hcl | $23 | $9225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in Manchester
- Helen RickettsManchester$6K
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Hui HuNorwich$19K
- Patrick GagnonMilford$15K
- Max Greger-MoserNew Haven$15K
- Richard ComshawRocky Hill$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.